Table 3 Assay of Remdesivir and Levodropropizine using the suggested flourimetric approach in single-component dosage forms and co-formulated dosage forms
Remdesivir-Eva® 100 mg/vial | Tussistop® 60 mg/tablet | Co-formulated dosage form | |||||
|---|---|---|---|---|---|---|---|
Remdesivir | Levodropropizine | ||||||
Conc. (ng/mL) | R% * | Conc. (ng/mL) | R% * | Conc. (ng/mL) | R %* | Conc. (ng/mL) | R % * |
25 | 99.38 | 15 | 98.27 | 25 | 98.94 | 15 | 98.12 |
50 | 98.71 | 30 | 99.01 | 50 | 98.62 | 30 | 99.20 |
75 | 101.95 | 45 | 98.12 | 75 | 101.84 | 45 | 98.34 |
100 | 100.69 | 60 | 100.39 | 100 | 100.56 | 60 | 100.47 |
125 | 101.27 | 75 | 101.46 | 125 | 101.37 | 75 | 100.86 |
Mean | 100.40 | Mean | 99.45 | Mean | 100.27 | Mean | 99.40 |
RSD% | 1.331 | RSD% | 1.447 | RSD% | 1.434 | RSD% | 1.241 |